Eyenovia will include a broad patient population, including patients with chronic angle closure glaucoma, open-angle glaucoma and ocular hypertension, in a phase 3 trial of MicroProst, according to a press release.
MicroProst (microdose latanoprost with Optejet delivery) uses Eyenovia’s piezo-print delivery technology to deliver microdoses of IOP-lowering medications.
“If approved, MicroProst could have one of the widest indications of commercially available IOP-lowering therapies, as well as represent the first FDA-approved drug specifically indicated for chronic angle closure glaucoma,”
Uncategorized